Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NHI Prices Recommended for Approval for 6 Products
September 12, 2005
- Medical Expenditure for Clinics Rose 2.5% in FY2004: HIB
September 12, 2005
- AstraZeneca Aims for 4.2% Share of Domestic Market by 2010
September 12, 2005
- R&D NEWS IN BRIEF
September 12, 2005
- SELF-MEDICATION NEWS IN BRIEF
September 12, 2005
- Statistics
September 12, 2005
- COMMENTARY 6 articles
September 12, 2005
- Tonic Drinks: Sales of New Quasi-drugs Outpace OTC Products
September 5, 2005
- Uncollected Medical Fees - Why Don't Patients Pay?
September 5, 2005
- HUMAN RESOURCE NEWS IN BRIEF
September 5, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 5, 2005
- 1st Qtr Business Results
September 5, 2005
- JMACCT to Determine Number of Patients Seen by Each Institution by Disease
September 5, 2005
- BUSINESS NEWS IN BRIEF
September 5, 2005
- New Regenerative Therapy Using Cell Sheets Reported: Dr Okano
September 5, 2005
- Merger Preparations Going Smoothly: Sumitomo Pharm.
September 5, 2005
- SMOs Expected to Outpace CROs in Future Growth: Seminar
September 5, 2005
- Takeda Preparing to Launch Rozerem in US
September 5, 2005
- R&D NEWS IN BRIEF
September 5, 2005
- REGULATORY NEWS IN BRIEF
September 5, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…